GlassScriptPhysician profile
Robert Suk Kang
NPI 1316059348
$3,010.91
in general payments reported to CMS, 2019-2025
16 companies · $942 in 2025
The $942 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.22 · 2021: $172 · 2023: $196 · 2024: $1,661 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139 · Travel and Lodging: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.92 |
| Travel and Lodging | $660.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,510.54 | 2023-2025 | Na, Xpress Loprofile, Vsp System, Vsp Cranial |
| Abbvie INC. | $446.42 | 2024-2025 | |
| Acera Surgical, INC. | $354.50 | 2021-2025 | Restrata Wound Matrix |
| Axogen | $138.70 | 2025 | |
| Integra Lifesciences Corporation | $135.47 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kls-Martin L.P. | $125.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.79 | 2023 | Imfinzi |
| Medtronic, INC. | $49.24 | 2025 | Rapidvac |
| Merck Sharp & Dohme LLC | $48.86 | 2024 | Keytruda |
| Smith+Nephew, INC. | $37.97 | 2023 | Grafix |
| Takeda Pharmaceuticals U.S.A., INC. | $29.84 | 2023 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $23.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.23 | 2019 | |
| Mirati Therapeutics, INC. | $16.92 | 2024 | Krazati |
| Janssen Biotech, INC. | $15.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.